Abstract:INTRODUCTIONDespite promising preclinical studies, BRAF/MEK inhibition with vemurafenib in melanoma brain metastases (MBM) has suboptimal durable response in humans. Thrombospondin 1 (THBS1), a matricellular protein, is upregulated in vemurafenib-resistant metastatic melanoma, and its inhibition reverses BRAF inhibitor chemoresistance. However, the characteristics of THBS1-mediated signaling pathways as well as methods of inhibition require further exploration in the context of MBM. OBJECTIVETo characterize THBS1-mediated signaling pathways in MBM and evaluate the therapeutic potential of targeting THBS1 pathways. METHODSWe analyzed human parenchymal MBM samples using publicly available single-cell RNA sequencing (scRNA-seq) data. Protein-protein interaction networks were assessed using the STRING database. Syngeneic B16 melanoma cells were intracranially implanted in C57BL/6J mice and treated with intraperitoneal injection of FGF7/FGFR2 small-molecule inhibitor Infigratinib or PBS (sham). Mice were immunophenotyped using flow cytometry and monitored for survival. RESULTSTHBS1 is highly upregulated in immunosuppressive MBM-associated cell populations such as S100A8+ Metastasis-Associated Macrophages and Mesenchymal Stromal Cell-like cells. Gene set enrichment analysis of THBS1-positive cells paradoxically revealed upregulation of inflammation-associated gene sets. Differential expression analysis identified Fibroblast Growth Factor 7 (FGF7) as strongly co-expressed in THBS1-positive MBM cells, and STRING-DB confirmed close protein-protein interactions between FGF7 and THBS1. In vivo inhibition using Infigratinib for FGF7's receptor, FGFR2, decreased the proportion of monocytic myeloid-derived suppressor cells (M-MDSCs) (P=0.030), increased T-cell activation marker IFN-y (P=0.027) and proliferation marker CD69 (P=0.047), and resulted in improved overall survival (P=0.0001). CONCLUSIONMBM scRNA-seq data suggests that THBS1 is associated with inflammation-induced immunosuppression. Inhibiting the FGF7/FGFR2-THBS1 axis with Infigratinib modulates the tumor microenvironment by reducing immunosuppressive M-MDSCs and increasing T cell activation and proliferation. This data supports THBS1 inhibition as a viable therapeutic option that in the future can also be combined with other current immunotherapeutic strategies.

Intratumoral injection of pEGFC1-IGFBP7 inhibits malignant melanoma growth in C57BL/6J mice by inducing apoptosis and down-regulating VEGF expression

In-vivo Transfection of Pcdna3.1-Igfbp7 Inhibits Melanoma Growth in Mice Through Apoptosis Induction and VEGF Downexpression

Pegfc1-Igfbp7 Induces Apoptosis of Malignant Melanoma Cell Line SK-MEL-28

The FGF2-binding Peptide P7 Inhibits Melanoma Growth in Vitro and in Vivo

Targeting Hypoxia-inducible Factor-1|[alpha]| With Tf|[ndash]|PEI|[ndash]|shRNA Complex via Transferrin Receptor|[ndash]|mediated Endocytosis Inhibits Melanoma Growth

Hmgb1-IL-23-IL-17-IL-6-Stat3 Axis Promotes Tumor Growth in Murine Models of Melanoma

Anti-Tumor Effects of Engineered VNP20009-Abvec-Igκ-mPD-1 Strain in Melanoma Mice Via Combining the Oncolytic Therapy and Immunotherapy

Therapeutic effect of gene-therapy in combination with local X-irradiation in a mouse malignant melanoma model.

Down-regulation of MFG-E8 by RNA interference combined with doxorubicin triggers melanoma destruction

EIF3H knockdown inhibits malignant melanoma through regulating cell proliferation, apoptosis and cell cycle

Polyethylenimine-complexed Plasmid Particles Targeting Focal Adhesion Kinase Function As Melanoma Tumor Therapeutics

Efficacy and advantage of immunotherapy for melanoma via intramuscular co-expression of plasmid-encoded PD-1 and CTLA-4 scFvs

Formyl Peptide Receptor Suppresses Melanoma Development and Promotes NK Cell Migration

Regulator of G protein signaling 4 inhibits human melanoma cells proliferation and invasion through the PI3K/AKT signaling pathway

Regulation Of Epidermal Growth Factor Receptor Signaling By Plasmid-Based Microrna-7 Inhibits Human Malignant Gliomas Growth And Metastasis In Vivo

In vitro and in vivo effects of an anti-mouse endoglin (CD105)-immunotoxin on the early stages of mouse B16MEL4A5 melanoma tumours

Silencing FYVE, RhoGEF, and PH Domain Containing 1 (FGD1) Suppresses Melanoma Progression by Inhibiting PI3K/AKT Signaling Pathway

Anti-tumor effect of adenovirus-mediated gene transfer of pigment epithelium-derived factor on mouse B16-F10 melanoma

Investigation of a Plasmid Containing a Novel Immunotoxin VEGF165‐PE38 Gene for Antiangiogenic Therapy in a Malignant Glioma Model

Tmic-32. Infigratinib Inhibition Of The Thbs1 Pathway In Melanoma Brain Metastasis

Preparation and Functional Characterization of Human Vascular Endothelial Growth Factor-Melittin Fusion Protein with Analysis of the Antitumor Activity in Vitro and in Vivo.